Charles River Laboratories International (CRL) Financials

$119.49 +1.03 (+0.87%)

Closing price 03:59 PM Eastern

Extended Trading

$117.53 -1.96 (-1.64%)

As of 06:11 PM Eastern

Annual Income Statements for Charles River Laboratories International

This table shows Charles River Laboratories International's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/26/2015	12/31/2016	12/30/2017	12/29/2018	12/28/2019	12/26/2020	12/25/2021	12/31/2022	12/30/2023	12/28/2024
Net Income / (Loss) Attributable to Common Shareholders	149	155	123	226	252	364	391	486	475	22
Consolidated Net Income / (Loss)	151	156	125	229	254	365	399	493	480	25
Net Income / (Loss) Continuing Operations	152	156	126	227	254	365	399	493	480	25
Total Pre-Tax Income	195	223	297	282	304	447	481	623	581	93
Total Operating Income	206	238	288	331	351	433	590	651	617	227
Total Gross Profit	531	644	701	840	958	1,074	1,335	1,463	1,503	1,332
Total Revenue	1,363	1,681	1,858	2,266	2,621	2,924	3,540	3,976	4,129	4,050
Operating Revenue	1,363	1,681	1,858	2,266	2,621	2,924	3,540	3,976	4,129	4,050
Total Cost of Revenue	832	1,037	1,157	1,426	1,663	1,850	2,206	2,513	2,627	2,718
Operating Cost of Revenue	832	1,037	1,157	1,426	1,663	1,850	2,206	2,513	2,627	2,718
Total Operating Expenses	325	406	413	509	607	641	745	812	885	1,104
Selling, General & Admin Expense	300	365	371	444	518	529	620	665	748	751
Amortization Expense	24	42	41	65	90	112	125	147	137	138
Impairment Charge	-	-	-	-	-	-	-	0.00	0.00	215
Total Other Income / (Expense), net	-11	-15	8.67	-50	-47	14	-109	-28	-36	-134
Interest Expense	15	28	30	64	61	86	74	59	137	126
Interest & Investment Income	1.04	1.31	0.69	0.81	1.52	0.83	0.65	0.78	5.20	8.58
Other Income / (Expense), net	3.01	12	38	13	12	100	-36	31	96	-17
Income Tax Expense	43	67	171	54	50	82	82	130	101	68
Preferred Stock Dividends Declared	-	-	-	-	-	-	-	0.00	0.00	12
Net Income / (Loss) Attributable to Noncontrolling Interest	1.77	1.60	2.09	2.35	2.04	1.00	7.86	6.38	5.75	3.09
Basic Earnings per Share	$3.21	$3.29	$2.60	$4.72	$5.17	$7.35	$7.77	$9.57	$9.27	$0.20
Weighted Average Basic Shares Outstanding	46.50M	47.01M	47.48M	47.95M	48.73M	49.55M	50.29M	50.81M	51.23M	51.38M
Diluted Earnings per Share	$3.13	$3.23	$2.54	$4.62	$5.07	$7.20	$7.60	$9.48	$9.22	$0.20
Weighted Average Diluted Shares Outstanding	46.50M	47.96M	48.56M	49.02M	49.69M	50.61M	51.43M	51.30M	51.45M	51.63M
Weighted Average Basic & Diluted Shares Outstanding	46.50M	47.01M	47.40M	48M	48.96M	49.78M	50.49M	50.99M	51.35M	51.14M

This table shows Charles River Laboratories International's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/24/2022	12/31/2022	4/1/2023	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024
Net Income / (Loss) Attributable to Common Shareholders	96	187	103	97	87	187	73	94	70	-214
Consolidated Net Income / (Loss)	98	189	104	99	88	189	74	94	70	-214
Net Income / (Loss) Continuing Operations	98	189	104	99	88	189	74	94	70	-214
Total Pre-Tax Income	123	245	131	129	113	209	99	120	91	-217
Total Operating Income	151	164	168	165	152	133	126	152	117	-168
Total Gross Profit	370	399	378	399	362	364	345	354	349	284
Total Revenue	989	1,100	1,029	1,060	1,027	1,013	1,012	1,026	1,010	1,003
Operating Revenue	989	1,100	1,029	1,060	1,027	1,013	1,012	1,026	1,010	1,003
Total Cost of Revenue	619	701	652	661	665	649	667	672	661	718
Operating Cost of Revenue	619	701	652	661	665	649	667	672	661	718
Total Operating Expenses	219	235	210	234	210	231	219	202	232	452
Selling, General & Admin Expense	184	200	175	200	176	197	186	170	199	196
Amortization Expense	36	35	35	34	34	34	33	32	32	41
Total Other Income / (Expense), net	-28	81	-37	-36	-39	76	-27	-32	-26	-49
Interest Expense	11	35	34	35	34	34	35	33	30	28
Interest & Investment Income	0.12	0.34	0.81	1.43	1.37	1.59	2.20	3.01	1.53	1.84
Other Income / (Expense), net	-17	116	-3.28	-2.66	-6.26	108	5.83	-2.24	2.59	-23
Income Tax Expense	25	56	27	29	25	20	25	25	21	-3.04
Net Income / (Loss) Attributable to Noncontrolling Interest	1.14	1.70	0.82	2.42	0.63	1.87	6.75	3.97	0.64	-8.27
Basic Earnings per Share	$1.90	$3.68	$2.02	$1.89	$1.70	$3.66	$1.31	$1.75	$1.34	($4.20)
Weighted Average Basic Shares Outstanding	50.87M	50.81M	51.10M	51.22M	51.28M	51.23M	51.44M	51.55M	51.39M	51.38M
Diluted Earnings per Share	$1.88	$3.66	$2.01	$1.89	$1.69	$3.63	$1.30	$1.74	$1.33	($4.17)
Weighted Average Diluted Shares Outstanding	51.28M	51.30M	51.43M	51.47M	51.61M	51.45M	51.84M	51.85M	51.58M	51.63M
Weighted Average Basic & Diluted Shares Outstanding	50.88M	50.99M	51.18M	51.27M	51.30M	51.35M	51.51M	51.63M	51.14M	51.14M

This table details how cash moves in and out of Charles River Laboratories International's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/26/2015	12/31/2016	12/30/2017	12/29/2018	12/28/2019	12/26/2020	12/25/2021	12/31/2022	12/30/2023	12/28/2024
Net Change in Cash & Equivalents	-30	2.93	35	40	43	-6.93	13	-5.10	43	-79
Net Cash From Operating Activities	307	317	318	441	481	547	761	620	684	735
Net Cash From Continuing Operating Activities	307	317	318	441	481	547	761	620	684	735
Net Income / (Loss) Continuing Operations	152	156	126	227	254	365	399	493	480	25
Consolidated Net Income / (Loss)	151	156	125	229	254	365	399	493	480	25
Depreciation Expense	95	127	131	162	198	235	266	304	314	362
Non-Cash Adjustments To Reconcile Net Income	29	60	19	75	34	-18	129	42	27	452
Changes in Operating Assets and Liabilities, net	31	-26	43	-23	-4.82	-36	-32	-219	-138	-104
Net Cash From Investing Activities	-328	-693	-73	-955	-682	-602	-1,438	-608	-563	-245
Net Cash From Continuing Investing Activities	-328	-693	-73	-955	-682	-602	-1,438	-608	-563	-245
Purchase of Property, Plant & Equipment	-63	-55	-82	-140	-141	-167	-229	-325	-319	-233
Acquisitions	-248	-648	-25	-825	-516	-419	-1,293	-283	-195	-5.48
Purchase of Investments	-34	-40	-46	-25	-22	-27	-46	-158	-54	-53
Divestitures	0.00	0.00	72	-	0.00	0.00	123	163	0.00	0.00
Sale and/or Maturity of Investments	20	48	9.13	36	0.94	11	6.53	4.55	6.67	42
Other Investing Activities, net	-2.22	3.69	-0.52	-0.81	-3.89	-1.07	0.26	-9.35	-2.29	4.55
Net Cash From Financing Activities	-7.26	381	-208	558	232	47	673	-42	-86	-551
Net Cash From Continuing Financing Activities	-7.26	381	-208	558	232	47	673	-42	-86	-551
Repayment of Debt	-422	-675	-377	-2,221	-3,143	-2,206	-6,281	-2,940	-856	-1,525
Repurchase of Common Equity	-117	-12	-107	-14	-18	-24	-41	-39	-24	-119
Issuance of Debt	493	1,045	237	2,755	3,358	2,231	6,951	2,952	776	1,082
Other Financing Activities, net	39	23	39	38	35	47	43	-16	18	12
Effect of Exchange Rate Changes	-	-	-	-	11	0.79	18	26	8.04	-17

This table details how cash moves in and out of Charles River Laboratories International's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/24/2022	12/31/2022	4/1/2023	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024
Net Change in Cash & Equivalents	-11	45	-32	-0.11	-43	119	54	-158	31	-6.07
Net Cash From Operating Activities	133	235	109	148	205	221	130	194	252	159
Net Cash From Continuing Operating Activities	133	235	109	148	205	221	130	194	252	159
Net Income / (Loss) Continuing Operations	98	189	104	99	88	189	74	94	70	-214
Consolidated Net Income / (Loss)	98	189	104	99	88	189	74	94	70	-214
Depreciation Expense	75	78	77	78	79	81	85	86	88	102
Non-Cash Adjustments To Reconcile Net Income	38	-80	33	8.08	44	-58	25	38	42	347
Changes in Operating Assets and Liabilities, net	-77	49	-105	-37	-5.37	9.77	-55	-25	52	-76
Net Cash From Investing Activities	-92	44	-169	-77	-80	-238	-86	-62	-21	-76
Net Cash From Continuing Investing Activities	-92	44	-169	-77	-80	-238	-86	-62	-21	-76
Purchase of Property, Plant & Equipment	-72	-89	-107	-67	-66	-78	-79	-39	-39	-76
Purchase of Investments	-21	-29	-13	-10	-14	-18	-14	-22	-9.73	-7.61
Sale and/or Maturity of Investments	2.90	1.45	1.95	0.99	1.01	2.71	7.50	4.86	27	2.22
Other Investing Activities, net	-2.17	-2.40	-0.96	-0.10	-0.99	-0.25	-0.28	-0.09	0.01	4.91
Net Cash From Financing Activities	-52	-249	25	-71	-163	124	18	-286	-208	-76
Net Cash From Continuing Financing Activities	-52	-249	25	-71	-163	124	18	-286	-208	-76
Repayment of Debt	-657	-410	-157	-160	-218	-321	-295	-706	-343	-181
Repurchase of Common Equity	-0.02	-0.16	-19	-4.97	-0.04	-0.14	-9.35	-8.91	-101	-0.12
Issuance of Debt	618	154	193	89	51	443	301	440	236	105
Other Financing Activities, net	-13	7.40	9.08	3.93	3.94	1.16	22	-11	0.78	0.77
Effect of Exchange Rate Changes	-0.03	15	1.67	-0.16	-6.19	13	-8.39	-3.34	7.70	-13

This table presents Charles River Laboratories International's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/26/2015	12/31/2016	12/30/2017	12/29/2018	12/28/2019	12/26/2020	12/25/2021	12/31/2022	12/30/2023	12/28/2024
Total Assets	2,068	2,712	2,930	3,856	4,693	5,491	7,024	7,603	8,195	7,528
Total Current Assets	559	657	827	898	1,021	1,201	1,274	1,439	1,609	1,403
Cash & Equivalents	118	118	164	195	238	228	241	234	277	195
Accounts Receivable	270	364	430	472	514	618	643	752	780	721
Inventories, net	94	96	115	128	161	186	199	256	380	279
Prepaid Expenses	30	34	118	102	109	169	191	197	171	209
Plant, Property, & Equipment, net	678	756	782	933	1,044	0.00	1,291	1,466	1,640	1,604
Total Noncurrent Assets	831	1,299	1,321	2,025	2,627	4,290	4,459	4,698	4,947	4,521
Long-Term Investments	-	-	-	-	-	-	201	312	244	218
Goodwill	439	788	805	1,247	1,541	1,809	2,712	2,850	3,095	2,847
Intangible Assets	281	394	370	611	689	788	1,061	955	864	723
Noncurrent Deferred & Refundable Income Taxes	40	29	23	23	45	38	40	41	40	42
Other Noncurrent Operating Assets	72	88	124	144	213	1,477	444	540	703	691
Total Liabilities & Shareholders' Equity	2,068	2,712	2,930	3,856	4,693	5,491	7,024	7,603	8,195	7,528
Total Liabilities	1,303	1,858	1,866	2,518	3,026	3,347	4,432	4,579	4,536	4,020
Total Current Liabilities	312	430	464	558	710	840	1,033	1,092	1,055	994
Accounts Payable	37	68	78	66	111	122	198	206	169	140
Accrued Expenses	89	84	90	107	139	150	229	220	228	232
Current Deferred Revenue	81	128	118	145	172	208	220	264	242	248
Current Employee Benefit Liabilities	73	93	101	137	159	207	246	197	213	179
Other Current Liabilities	13	27	44	71	91	102	140	205	203	194
Total Noncurrent Liabilities	991	1,428	1,402	1,959	2,316	2,507	3,399	3,488	3,481	3,026
Long-Term Debt	846	1,208	1,114	1,637	1,850	1,930	2,664	2,708	2,647	2,240
Noncurrent Deferred & Payable Income Tax Liabilities	48	56	90	144	167	217	240	216	191	107
Other Noncurrent Operating Liabilities	89	159	195	179	299	361	496	565	642	679
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	28	15	17	19	29	25	53	42	57	41
Total Equity & Noncontrolling Interests	738	839	1,047	1,320	1,638	2,118	2,539	2,981	3,602	3,467
Total Preferred & Common Equity	733	837	1,045	1,317	1,635	2,115	2,535	2,976	3,597	3,462
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	733	837	1,045	1,317	1,635	2,115	2,535	2,976	3,597	3,462
Common Stock	2,399	2,478	2,561	1,448	1,532	1,628	1,719	1,805	1,906	1,967
Retained Earnings	11	165	289	42	280	625	981	1,433	1,887	1,812
Treasury Stock	-1,541	-1,553	-1,660	-0.06	0.00	0.00	0.00	0.00	0.00	0.00
Accumulated Other Comprehensive Income / (Loss)	-136	-254	-145	-173	-178	-139	-165	-262	-196	-317
Noncontrolling Interest	4.49	2.36	2.33	2.45	3.24	3.57	4.16	4.79	5.39	5.45

This table presents Charles River Laboratories International's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/24/2022	12/31/2022	4/1/2023	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024
Total Assets	7,383	7,603	7,699	7,772	7,607	8,195	8,153	7,948	8,004	7,528
Total Current Assets	1,415	1,439	1,448	1,505	1,444	1,609	1,668	1,499	1,495	1,403
Cash & Equivalents	194	234	202	200	157	277	327	179	210	195
Accounts Receivable	771	752	788	801	799	780	787	762	754	721
Inventories, net	262	256	263	285	293	380	361	349	336	279
Prepaid Expenses	189	197	196	218	195	171	193	209	194	209
Plant, Property, & Equipment, net	1,381	1,466	1,494	1,530	1,525	1,640	1,619	1,614	1,640	1,604
Total Noncurrent Assets	4,587	4,698	4,757	4,738	4,637	4,947	4,866	4,835	4,869	4,521
Long-Term Investments	-	312	294	300	302	244	244	232	236	218
Goodwill	2,776	2,850	2,902	2,917	2,885	3,095	3,070	3,080	3,125	2,847
Intangible Assets	968	955	958	930	886	864	828	800	778	723
Noncurrent Deferred & Refundable Income Taxes	40	41	41	39	34	40	37	36	38	42
Other Noncurrent Operating Assets	803	540	562	553	530	703	688	687	692	691
Total Liabilities & Shareholders' Equity	7,383	7,603	7,699	7,772	7,607	8,195	8,153	7,948	8,004	7,528
Total Liabilities	4,711	4,579	4,543	4,472	4,256	4,536	4,449	4,175	4,176	4,020
Total Current Liabilities	1,014	1,092	981	1,008	994	1,055	955	948	1,012	994
Accounts Payable	182	206	120	140	136	169	130	133	136	140
Accrued Expenses	197	220	221	221	198	228	191	192	208	232
Current Deferred Revenue	251	264	262	257	250	242	256	247	252	248
Current Employee Benefit Liabilities	200	197	176	191	224	213	190	177	211	179
Other Current Liabilities	182	205	202	199	185	203	188	198	205	194
Total Noncurrent Liabilities	3,697	3,488	3,561	3,465	3,262	3,481	3,494	3,228	3,164	3,026
Long-Term Debt	2,937	2,708	2,744	2,678	2,514	2,647	2,660	2,409	2,327	2,240
Noncurrent Deferred & Payable Income Tax Liabilities	196	216	212	207	185	191	180	165	168	107
Other Noncurrent Operating Liabilities	564	565	605	579	563	642	653	653	670	679
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	39	42	43	42	40	57	58	46	41	41
Total Equity & Noncontrolling Interests	2,633	2,981	3,114	3,258	3,311	3,602	3,646	3,727	3,787	3,467
Total Preferred & Common Equity	2,627	2,976	3,109	3,252	3,306	3,597	3,640	3,723	3,782	3,462
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,627	2,976	3,109	3,252	3,306	3,597	3,640	3,723	3,782	3,462
Common Stock	1,781	1,805	1,831	1,851	1,878	1,906	1,940	1,957	1,972	1,967
Retained Earnings	1,280	1,433	1,536	1,633	1,720	1,887	1,960	2,054	2,123	1,812
Treasury Stock	-38	0.00	-19	-24	-24	0.00	-9.35	-18	-120	0.00
Accumulated Other Comprehensive Income / (Loss)	-396	-262	-239	-208	-268	-196	-250	-270	-193	-317
Noncontrolling Interest	5.89	4.79	5.29	5.85	4.77	5.39	5.72	4.29	4.85	5.45

This table displays calculated financial ratios and metrics derived from Charles River Laboratories International's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/26/2015	12/31/2016	12/30/2017	12/29/2018	12/28/2019	12/26/2020	12/25/2021	12/31/2022	12/30/2023	12/28/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	5.06%	23.34%	10.48%	21.99%	15.67%	11.55%	21.08%	12.31%	3.86%	-1.92%
EBITDA Growth	6.20%	23.54%	21.60%	10.77%	10.88%	36.70%	6.76%	20.24%	4.22%	-44.24%
EBIT Growth	11.18%	19.03%	30.77%	5.70%	5.46%	46.57%	3.99%	23.02%	4.59%	-70.42%
NOPAT Growth	23.57%	3.56%	-26.70%	119.25%	9.75%	20.51%	38.42%	5.18%	-0.90%	-87.89%
Net Income Growth	17.85%	3.49%	-19.77%	82.32%	11.08%	43.79%	9.18%	23.51%	-2.48%	-94.74%
EPS Growth	17.67%	3.19%	-21.36%	81.89%	9.74%	42.01%	5.56%	24.74%	-2.74%	-97.83%
Operating Cash Flow Growth	21.70%	3.28%	0.37%	38.69%	9.02%	13.65%	39.19%	-18.55%	10.37%	7.41%
Free Cash Flow Firm Growth	-116.52%	-802.84%	116.93%	-1,096.99%	56.87%	-5.83%	-90.64%	133.18%	-163.25%	669.25%
Invested Capital Growth	14.53%	30.14%	3.67%	37.04%	17.99%	17.44%	23.57%	7.74%	11.57%	-7.78%
Revenue Q/Q Growth	1.81%	7.20%	0.63%	5.74%	3.54%	3.54%	3.33%	5.15%	-2.05%	-0.27%
EBITDA Q/Q Growth	2.72%	7.86%	0.79%	4.80%	9.31%	12.50%	-2.88%	13.18%	-3.36%	-41.70%
EBIT Q/Q Growth	5.50%	7.50%	1.77%	4.58%	11.53%	16.71%	-5.24%	18.11%	-5.15%	-67.15%
NOPAT Q/Q Growth	3.81%	9.48%	-39.64%	83.08%	-0.43%	8.03%	8.82%	-4.70%	1.14%	-85.83%
Net Income Q/Q Growth	3.20%	8.97%	-37.19%	64.01%	8.69%	21.11%	-1.08%	11.12%	-0.03%	-94.09%
EPS Q/Q Growth	2.96%	9.12%	-38.05%	66.79%	8.57%	19.80%	-1.81%	11.66%	-0.32%	-97.50%
Operating Cash Flow Q/Q Growth	7.38%	-0.72%	1.79%	3.70%	9.25%	-7.18%	13.57%	0.90%	-1.98%	-7.73%
Free Cash Flow Firm Q/Q Growth	-267.52%	21.87%	-66.00%	13.23%	-5.17%	-306.75%	57.08%	-47.29%	-117.44%	283.81%
Invested Capital Q/Q Growth	-0.23%	-3.45%	-2.61%	-0.31%	0.01%	5.31%	-6.49%	-4.28%	7.02%	-6.53%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	38.96%	38.30%	37.73%	37.07%	36.56%	36.72%	37.70%	36.79%	36.39%	32.88%
EBITDA Margin	22.32%	22.36%	24.61%	22.35%	21.42%	26.25%	23.15%	24.78%	24.87%	14.14%
Operating Margin	15.14%	14.13%	15.52%	14.62%	13.40%	14.80%	16.66%	16.37%	14.95%	5.61%
EBIT Margin	15.36%	14.83%	17.55%	15.21%	13.87%	18.22%	15.65%	17.14%	17.26%	5.21%
Profit (Net Income) Margin	11.08%	9.30%	6.75%	10.09%	9.69%	12.49%	11.27%	12.39%	11.63%	0.62%
Tax Burden Percent	77.31%	70.14%	42.25%	81.20%	83.55%	81.70%	82.97%	79.07%	82.64%	27.16%
Interest Burden Percent	93.30%	89.41%	91.08%	81.73%	83.67%	83.93%	86.78%	91.41%	81.55%	44.17%
Effective Tax Rate	22.20%	29.98%	57.71%	19.34%	16.45%	18.30%	17.03%	20.93%	17.36%	72.84%
Return on Invested Capital (ROIC)	11.28%	9.51%	6.05%	11.00%	9.58%	9.81%	11.24%	10.30%	9.30%	1.11%
ROIC Less NNEP Spread (ROIC-NNEP)	9.90%	8.45%	6.39%	7.86%	7.06%	10.50%	6.68%	9.29%	7.91%	-0.73%
Return on Net Nonoperating Assets (RNNOA)	9.28%	9.80%	7.03%	8.05%	7.33%	9.37%	5.60%	7.25%	5.08%	-0.40%
Return on Equity (ROE)	20.56%	19.31%	13.08%	19.04%	16.91%	19.18%	16.84%	17.54%	14.38%	0.71%
Cash Return on Invested Capital (CROIC)	-2.27%	-16.68%	2.45%	-20.26%	-6.93%	-6.23%	-9.84%	2.84%	-1.64%	9.21%
Operating Return on Assets (OROA)	10.63%	10.43%	11.56%	10.16%	8.50%	10.46%	8.85%	9.32%	9.02%	2.68%
Return on Assets (ROA)	7.67%	6.54%	4.45%	6.74%	5.94%	7.17%	6.37%	6.74%	6.08%	0.32%
Return on Common Equity (ROCE)	19.65%	18.72%	12.84%	18.73%	16.61%	18.87%	16.54%	17.22%	14.14%	0.70%
Return on Equity Simple (ROE_SIMPLE)	20.61%	18.69%	12.00%	17.36%	15.54%	17.28%	15.73%	16.55%	13.36%	0.73%
Net Operating Profit after Tax (NOPAT)	161	166	122	267	293	354	489	515	510	62
NOPAT Margin	11.78%	9.89%	6.56%	11.80%	11.19%	12.09%	13.82%	12.95%	12.35%	1.52%
Net Nonoperating Expense Percent (NNEP)	1.38%	1.06%	-0.33%	3.14%	2.52%	-0.69%	4.56%	1.01%	1.39%	1.84%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	9.05%	8.16%	1.08%
Cost of Revenue to Revenue	61.04%	61.70%	62.27%	62.93%	63.44%	63.28%	62.30%	63.21%	63.61%	67.12%
SG&A Expenses to Revenue	22.04%	21.69%	19.99%	19.59%	19.75%	18.09%	17.51%	16.73%	18.11%	18.54%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	23.81%	24.17%	22.21%	22.45%	23.16%	21.92%	21.04%	20.41%	21.44%	27.27%
Earnings before Interest and Taxes (EBIT)	209	249	326	345	363	533	554	681	713	211
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	304	376	457	506	562	768	820	985	1,027	573
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.09	4.31	4.96	4.08	4.54	5.92	7.35	3.72	3.37	2.75
Price to Tangible Book Value (P/TBV)	277.92	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.74	2.14	2.79	2.37	2.83	4.28	5.26	2.79	2.94	2.35
Price to Earnings (P/E)	25.01	23.30	42.02	23.74	29.44	34.37	47.65	22.80	25.55	428.75
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.00%	4.29%	2.38%	4.21%	3.40%	2.91%	2.10%	4.39%	3.91%	0.23%
Enterprise Value to Invested Capital (EV/IC)	2.97	2.40	3.02	2.44	2.74	3.67	4.34	2.56	2.47	2.14
Enterprise Value to Revenue (EV/Rev)	3.31	2.82	3.33	3.03	3.47	4.89	5.91	3.34	3.47	2.81
Enterprise Value to EBITDA (EV/EBITDA)	14.82	12.61	13.53	13.56	16.21	18.63	25.51	13.49	13.94	19.90
Enterprise Value to EBIT (EV/EBIT)	21.54	19.01	18.97	19.92	25.04	26.85	37.75	19.51	20.08	54.04
Enterprise Value to NOPAT (EV/NOPAT)	28.09	28.50	50.72	25.69	31.02	40.45	42.73	25.83	28.06	184.51
Enterprise Value to Operating Cash Flow (EV/OCF)	14.70	14.96	19.44	15.57	18.93	26.17	27.48	21.46	20.93	15.51
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	125.19	0.00	0.00	0.00	0.00	93.50	0.00	22.25
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.13	1.45	1.08	1.25	1.13	0.92	1.03	0.90	0.72	0.64
Long-Term Debt to Equity	1.11	1.41	1.05	1.22	1.11	0.90	1.03	0.90	0.72	0.64
Financial Leverage	0.94	1.16	1.10	1.02	1.04	0.89	0.84	0.78	0.64	0.55
Leverage Ratio	2.68	2.95	2.94	2.82	2.85	2.67	2.64	2.60	2.36	2.19
Compound Leverage Factor	2.50	2.64	2.68	2.31	2.38	2.24	2.29	2.38	1.93	0.97
Debt to Total Capital	52.99%	59.13%	51.84%	55.48%	53.12%	48.01%	50.68%	47.24%	41.98%	38.97%
Short-Term Debt to Total Capital	1.05%	1.31%	1.40%	1.05%	1.08%	1.22%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	51.95%	57.82%	50.43%	54.44%	52.03%	46.80%	50.68%	47.24%	41.98%	38.97%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	2.00%	0.81%	0.86%	0.70%	0.90%	0.70%	1.09%	0.82%	0.99%	0.81%
Common Equity to Total Capital	45.01%	40.06%	47.31%	43.82%	45.98%	51.28%	48.23%	51.93%	57.04%	60.22%
Debt to EBITDA	2.84	3.28	2.50	3.29	3.36	2.58	3.25	2.75	2.58	3.91
Net Debt to EBITDA	2.45	2.97	2.15	2.91	2.94	2.28	2.71	2.19	2.07	3.19
Long-Term Debt to EBITDA	2.78	3.21	2.44	3.23	3.29	2.51	3.25	2.75	2.58	3.91
Debt to NOPAT	5.37	7.43	9.39	6.24	6.44	5.60	5.44	5.26	5.19	36.28
Net Debt to NOPAT	4.64	6.72	8.05	5.51	5.62	4.95	4.54	4.20	4.17	29.59
Long-Term Debt to NOPAT	5.27	7.26	9.14	6.12	6.30	5.46	5.44	5.26	5.19	36.28
Altman Z-Score	2.86	2.27	2.95	2.28	2.45	3.34	3.52	2.59	2.80	2.45
Noncontrolling Interest Sharing Ratio	4.40%	3.06%	1.87%	1.66%	1.76%	1.60%	1.82%	1.86%	1.64%	1.52%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.79	1.53	1.78	1.61	1.44	1.43	1.23	1.32	1.52	1.41
Quick Ratio	1.24	1.12	1.28	1.20	1.06	1.01	0.86	0.90	1.00	0.92
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-32	-292	49	-492	-212	-225	-429	142	-90	512
Operating Cash Flow to CapEx	485.10%	573.18%	385.87%	314.98%	342.27%	328.16%	332.56%	190.82%	214.71%	315.31%
Free Cash Flow to Firm to Interest Expense	-2.14	-10.53	1.66	-7.72	-3.49	-2.60	-5.80	2.40	-0.66	4.05
Operating Cash Flow to Interest Expense	20.36	11.44	10.68	6.92	7.90	6.32	10.29	10.45	5.00	5.82
Operating Cash Flow Less CapEx to Interest Expense	16.16	9.44	7.91	4.72	5.59	4.40	7.20	4.97	2.67	3.97
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.69	0.70	0.66	0.67	0.61	0.57	0.57	0.54	0.52	0.52
Accounts Receivable Turnover	5.16	5.30	4.68	5.02	5.32	5.17	5.62	5.70	5.39	5.40
Inventory Turnover	9.11	10.95	10.97	11.74	11.53	10.68	11.46	11.05	8.26	8.25
Fixed Asset Turnover	2.01	2.35	2.42	2.64	2.65	0.00	0.00	2.88	2.66	2.50
Accounts Payable Turnover	23.61	19.73	15.81	19.79	18.71	15.82	13.76	12.44	14.02	17.58
Days Sales Outstanding (DSO)	70.69	68.83	78.01	72.66	68.67	70.64	64.99	64.04	67.74	67.65
Days Inventory Outstanding (DIO)	40.08	33.35	33.26	31.08	31.67	34.16	31.84	33.03	44.19	44.23
Days Payable Outstanding (DPO)	15.46	18.50	23.09	18.44	19.51	23.08	26.53	29.34	26.04	20.76
Cash Conversion Cycle (CCC)	95.31	83.67	88.18	85.30	80.83	81.72	70.30	67.74	85.89	91.12
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,520	1,979	2,051	2,811	3,317	3,895	4,813	5,186	5,786	5,335
Invested Capital Turnover	0.96	0.96	0.92	0.93	0.86	0.81	0.81	0.80	0.75	0.73
Increase / (Decrease) in Invested Capital	193	458	73	760	506	578	918	373	600	-450
Enterprise Value (EV)	4,511	4,740	6,184	6,867	9,102	14,301	20,910	13,296	14,315	11,393
Market Capitalization	3,734	3,606	5,184	5,373	7,420	12,521	18,631	11,086	12,127	9,520
Book Value per Share	$15.72	$17.68	$22.07	$27.39	$33.47	$42.51	$50.23	$58.50	$70.12	$67.69
Tangible Book Value per Share	$0.29	($7.29)	($2.74)	($11.24)	($12.19)	($9.69)	($24.54)	($16.29)	($7.06)	($2.12)
Total Capital	1,629	2,089	2,209	3,006	3,555	4,123	5,256	5,731	6,306	5,748
Total Debt	863	1,235	1,145	1,668	1,888	1,980	2,664	2,708	2,647	2,240
Total Long-Term Debt	846	1,208	1,114	1,637	1,850	1,930	2,664	2,708	2,647	2,240
Net Debt	745	1,117	981	1,473	1,650	1,751	2,221	2,162	2,127	1,827
Capital Expenditures (CapEx)	63	55	82	140	141	167	229	325	319	233
Debt-free, Cash-free Net Working Capital (DFCFNWC)	147	137	230	176	112	183	-0.30	114	277	214
Debt-free Net Working Capital (DFNWC)	265	255	394	371	350	412	241	347	554	409
Net Working Capital (NWC)	247	227	363	340	311	361	241	347	554	409
Net Nonoperating Expense (NNE)	9.52	9.96	-3.53	39	39	-12	91	22	30	36
Net Nonoperating Obligations (NNO)	755	1,125	987	1,473	1,650	1,751	2,221	2,162	2,127	1,827
Total Depreciation and Amortization (D&A)	95	127	131	162	198	235	266	304	314	362
Debt-free, Cash-free Net Working Capital to Revenue	10.75%	8.14%	12.40%	7.75%	4.26%	6.26%	-0.01%	2.86%	6.70%	5.29%
Debt-free Net Working Capital to Revenue	19.40%	15.14%	21.22%	16.37%	13.34%	14.08%	6.81%	8.74%	13.41%	10.10%
Net Working Capital to Revenue	18.15%	13.51%	19.55%	14.99%	11.87%	12.36%	6.81%	8.74%	13.41%	10.10%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.21	$3.29	$2.60	$4.72	$5.17	$7.35	$7.77	$9.57	$9.27	$0.20
Adjusted Weighted Average Basic Shares Outstanding	46.72M	47.37M	47.43M	47.95M	48.73M	49.55M	50.29M	50.81M	51.23M	51.38M
Adjusted Diluted Earnings per Share	$3.13	$3.23	$2.54	$4.62	$5.07	$7.20	$7.60	$9.48	$9.22	$0.20
Adjusted Weighted Average Diluted Shares Outstanding	46.72M	47.37M	47.43M	49.02M	49.69M	50.61M	51.43M	51.30M	51.45M	51.63M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$4.72	$5.17	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	46.72M	47.37M	47.43M	48.23M	48.96M	49.78M	50.49M	50.99M	51.35M	51.14M
Normalized Net Operating Profit after Tax (NOPAT)	161	166	202	267	293	354	489	515	510	310
Normalized NOPAT Margin	11.78%	9.89%	10.86%	11.80%	11.19%	12.09%	13.82%	12.95%	12.35%	7.65%
Pre Tax Income Margin	14.33%	13.26%	15.99%	12.43%	11.60%	15.29%	13.58%	15.67%	14.08%	2.30%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	13.90	9.00	10.95	5.40	5.97	6.16	7.50	11.49	5.21	1.67
NOPAT to Interest Expense	10.66	6.00	4.09	4.19	4.82	4.09	6.62	8.68	3.73	0.49
EBIT Less CapEx to Interest Expense	9.70	7.00	8.18	3.21	3.66	4.24	4.40	6.02	2.88	-0.18
NOPAT Less CapEx to Interest Expense	6.46	4.01	1.33	2.00	2.51	2.16	3.53	3.20	1.40	-1.36
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	77.76%	7.85%	85.22%	6.05%	7.12%	6.56%	10.21%	7.85%	5.03%	471.22%

This table displays calculated financial ratios and metrics derived from Charles River Laboratories International's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/24/2022	12/31/2022	4/1/2023	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.40%	21.52%	12.63%	8.92%	3.79%	-7.85%	-1.73%	-3.19%	-1.64%	-1.08%
EBITDA Growth	0.33%	47.41%	23.65%	7.10%	7.25%	-10.01%	-10.14%	-1.86%	-7.10%	-127.49%
EBIT Growth	-3.75%	59.74%	37.00%	9.93%	8.10%	-13.85%	-19.93%	-7.93%	-17.38%	-179.11%
NOPAT Growth	-9.93%	-14.34%	4.21%	-11.42%	-1.31%	-4.85%	-28.85%	-6.29%	-23.44%	-197.54%
Net Income Growth	-7.18%	35.24%	9.17%	-10.14%	-9.83%	-0.08%	-28.35%	-5.21%	-20.14%	-213.12%
EPS Growth	-6.47%	37.08%	11.05%	-11.27%	-10.11%	-0.82%	-35.32%	-7.94%	-21.30%	-214.88%
Operating Cash Flow Growth	-24.01%	2.40%	6.58%	-0.90%	54.73%	-5.88%	18.75%	30.66%	22.56%	-27.87%
Free Cash Flow Firm Growth	88.55%	68.06%	83.95%	129.17%	186.05%	-94.96%	-78.76%	-222.58%	-263.45%	169.39%
Invested Capital Growth	5.25%	7.74%	5.83%	-0.27%	-0.21%	11.57%	7.19%	5.36%	5.59%	-7.78%
Revenue Q/Q Growth	1.65%	11.19%	-6.41%	2.97%	-3.14%	-1.28%	-0.19%	1.44%	-1.59%	-0.71%
EBITDA Q/Q Growth	-6.73%	70.80%	-32.28%	-0.72%	-6.60%	43.31%	-32.38%	8.44%	-11.59%	-142.41%
EBIT Q/Q Growth	-8.99%	107.92%	-41.07%	-1.42%	-10.50%	65.70%	-45.23%	13.35%	-19.69%	-258.66%
NOPAT Q/Q Growth	-16.82%	5.66%	5.30%	-4.28%	-7.33%	1.86%	-21.25%	26.07%	-24.29%	-229.77%
Net Income Q/Q Growth	-11.79%	93.73%	-45.03%	-4.34%	-11.49%	114.67%	-60.58%	26.56%	-25.43%	-404.07%
EPS Q/Q Growth	-11.74%	94.68%	-45.08%	-5.97%	-10.58%	114.79%	-64.19%	33.85%	-23.56%	-413.53%
Operating Cash Flow Q/Q Growth	-11.17%	76.80%	-53.41%	35.42%	38.70%	7.54%	-41.21%	49.00%	30.10%	-36.71%
Free Cash Flow Firm Q/Q Growth	69.07%	-63.34%	33.20%	186.46%	-8.79%	-470.09%	38.75%	40.72%	-21.63%	257.12%
Invested Capital Q/Q Growth	-1.37%	-4.28%	4.24%	1.34%	-1.31%	7.02%	0.14%	-0.39%	-1.09%	-6.53%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	37.43%	36.27%	36.69%	37.64%	35.25%	35.92%	34.09%	34.47%	34.56%	28.35%
EBITDA Margin	21.13%	32.45%	23.48%	22.64%	21.83%	31.69%	21.47%	22.95%	20.62%	-8.81%
Operating Margin	15.26%	14.89%	16.31%	15.56%	14.76%	13.12%	12.45%	14.78%	11.63%	-16.73%
EBIT Margin	13.58%	25.40%	15.99%	15.31%	14.15%	23.75%	13.03%	14.56%	11.88%	-18.99%
Profit (Net Income) Margin	9.87%	17.19%	10.10%	9.38%	8.57%	18.64%	7.36%	9.19%	6.96%	-21.32%
Tax Burden Percent	79.29%	77.21%	79.33%	77.29%	77.98%	90.54%	75.23%	78.78%	77.04%	98.60%
Interest Burden Percent	91.62%	87.67%	79.60%	79.28%	77.71%	86.72%	75.12%	80.08%	76.04%	113.87%
Effective Tax Rate	20.71%	22.79%	20.67%	22.71%	22.02%	9.47%	24.77%	21.22%	22.96%	0.00%
Return on Invested Capital (ROIC)	8.66%	9.15%	10.07%	9.16%	8.97%	8.94%	6.88%	8.44%	6.55%	-8.53%
ROIC Less NNEP Spread (ROIC-NNEP)	7.85%	12.00%	8.82%	8.04%	7.71%	12.14%	5.94%	7.23%	5.52%	-13.40%
Return on Net Nonoperating Assets (RNNOA)	8.29%	9.37%	7.09%	6.67%	6.15%	7.79%	3.76%	4.27%	3.03%	-7.39%
Return on Equity (ROE)	16.96%	18.52%	17.17%	15.84%	15.11%	16.73%	10.64%	12.71%	9.57%	-15.92%
Cash Return on Invested Capital (CROIC)	5.11%	2.84%	4.28%	9.49%	9.53%	-1.64%	1.50%	3.02%	2.40%	9.21%
Operating Return on Assets (OROA)	7.11%	13.81%	8.86%	8.36%	7.96%	12.41%	6.76%	7.55%	6.18%	-9.78%
Return on Assets (ROA)	5.17%	9.35%	5.59%	5.12%	4.82%	9.75%	3.82%	4.77%	3.62%	-10.98%
Return on Common Equity (ROCE)	16.68%	18.17%	16.84%	15.59%	14.89%	16.45%	10.46%	12.53%	9.45%	-15.68%
Return on Equity Simple (ROE_SIMPLE)	16.88%	0.00%	16.13%	15.07%	14.53%	0.00%	12.39%	11.97%	11.32%	0.00%
Net Operating Profit after Tax (NOPAT)	120	126	133	127	118	120	95	119	90	-117
NOPAT Margin	12.10%	11.50%	12.94%	12.03%	11.51%	11.87%	9.37%	11.64%	8.96%	-11.71%
Net Nonoperating Expense Percent (NNEP)	0.81%	-2.86%	1.25%	1.13%	1.26%	-3.20%	0.94%	1.21%	1.02%	4.87%
Return On Investment Capital (ROIC_SIMPLE)	-	2.22%	-	-	-	1.93%	-	-	-	-2.06%
Cost of Revenue to Revenue	62.57%	63.73%	63.31%	62.36%	64.75%	64.08%	65.91%	65.53%	65.44%	71.65%
SG&A Expenses to Revenue	18.57%	18.15%	16.99%	18.85%	17.15%	19.45%	18.42%	16.55%	19.73%	19.52%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	22.17%	21.37%	20.38%	22.08%	20.49%	22.81%	21.64%	19.69%	22.94%	45.08%
Earnings before Interest and Taxes (EBIT)	134	279	165	162	145	241	132	149	120	-190
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	209	357	242	240	224	321	217	235	208	-88
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.63	3.72	3.31	3.31	3.04	3.37	3.82	2.86	2.71	2.75
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.52	2.79	2.51	2.58	2.38	2.94	3.38	2.61	2.52	2.35
Price to Earnings (P/E)	21.86	22.80	20.73	22.23	21.16	25.55	31.27	24.10	24.16	428.75
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.58%	4.39%	4.82%	4.50%	4.73%	3.91%	3.20%	4.15%	4.14%	0.23%
Enterprise Value to Invested Capital (EV/IC)	2.28	2.56	2.33	2.37	2.25	2.47	2.77	2.20	2.13	2.14
Enterprise Value to Revenue (EV/Rev)	3.26	3.34	3.08	3.11	2.88	3.47	3.90	3.11	3.00	2.81
Enterprise Value to EBITDA (EV/EBITDA)	14.16	13.49	12.20	12.40	11.43	13.94	16.01	12.72	12.39	19.90
Enterprise Value to EBIT (EV/EBIT)	21.36	19.51	17.34	17.54	16.17	20.08	23.61	19.02	18.95	54.04
Enterprise Value to NOPAT (EV/NOPAT)	22.82	25.83	24.10	25.68	24.09	28.06	33.99	27.37	27.92	184.51
Enterprise Value to Operating Cash Flow (EV/OCF)	20.07	21.46	20.09	20.78	17.41	20.93	22.79	16.92	15.28	15.51
Enterprise Value to Free Cash Flow (EV/FCFF)	45.70	93.50	56.00	24.96	23.55	0.00	191.71	74.62	91.19	22.25
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.10	0.90	0.87	0.81	0.75	0.72	0.72	0.64	0.61	0.64
Long-Term Debt to Equity	1.10	0.90	0.87	0.81	0.75	0.72	0.72	0.64	0.61	0.64
Financial Leverage	1.06	0.78	0.80	0.83	0.80	0.64	0.63	0.59	0.55	0.55
Leverage Ratio	2.81	2.60	2.54	2.55	2.49	2.36	2.31	2.22	2.17	2.19
Compound Leverage Factor	2.58	2.28	2.02	2.02	1.93	2.05	1.74	1.78	1.65	2.50
Debt to Total Capital	52.38%	47.24%	46.50%	44.80%	42.87%	41.98%	41.80%	38.97%	37.80%	38.97%
Short-Term Debt to Total Capital	0.04%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	52.34%	47.24%	46.50%	44.80%	42.87%	41.98%	41.80%	38.97%	37.80%	38.97%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.80%	0.82%	0.82%	0.81%	0.76%	0.99%	1.00%	0.81%	0.74%	0.81%
Common Equity to Total Capital	46.82%	51.93%	52.68%	54.39%	56.37%	57.04%	57.20%	60.21%	61.46%	60.22%
Debt to EBITDA	3.38	2.75	2.66	2.56	2.37	2.58	2.65	2.41	2.37	3.91
Net Debt to EBITDA	3.15	2.19	2.18	2.08	1.93	2.07	2.08	2.00	1.91	3.19
Long-Term Debt to EBITDA	3.37	2.75	2.66	2.56	2.37	2.58	2.65	2.41	2.37	3.91
Debt to NOPAT	5.44	5.26	5.25	5.30	4.98	5.19	5.63	5.20	5.34	36.28
Net Debt to NOPAT	5.08	4.20	4.30	4.31	4.07	4.17	4.42	4.31	4.32	29.59
Long-Term Debt to NOPAT	5.44	5.26	5.25	5.30	4.98	5.19	5.63	5.20	5.34	36.28
Altman Z-Score	2.09	2.42	2.31	2.42	2.42	2.61	2.87	2.55	2.47	2.28
Noncontrolling Interest Sharing Ratio	1.62%	1.86%	1.87%	1.56%	1.49%	1.64%	1.63%	1.39%	1.26%	1.52%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.40	1.32	1.48	1.49	1.45	1.52	1.75	1.58	1.48	1.41
Quick Ratio	0.95	0.90	1.01	0.99	0.96	1.00	1.17	0.99	0.95	0.92
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-151	-246	-164	142	130	-480	-294	-174	-212	333
Operating Cash Flow to CapEx	183.41%	263.70%	102.35%	219.82%	311.54%	282.09%	164.12%	490.14%	650.27%	210.75%
Free Cash Flow to Firm to Interest Expense	-13.24	-7.07	-4.78	4.06	3.84	-14.30	-8.39	-5.32	-7.00	11.79
Operating Cash Flow to Interest Expense	11.67	6.75	3.18	4.23	6.09	6.59	3.71	5.91	8.31	5.64
Operating Cash Flow Less CapEx to Interest Expense	5.31	4.19	0.07	2.30	4.13	4.25	1.45	4.70	7.04	2.97
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.52	0.54	0.55	0.55	0.56	0.52	0.52	0.52	0.52	0.52
Accounts Receivable Turnover	5.28	5.70	5.51	5.40	5.37	5.39	5.22	5.22	5.23	5.40
Inventory Turnover	10.70	11.05	10.70	9.71	9.66	8.26	8.47	8.36	8.42	8.25
Fixed Asset Turnover	0.00	2.88	0.00	0.00	2.90	2.66	2.64	2.59	2.57	2.50
Accounts Payable Turnover	15.32	12.44	14.96	14.98	16.85	14.02	21.16	19.42	19.46	17.58
Days Sales Outstanding (DSO)	69.08	64.04	66.29	67.62	67.97	67.74	69.92	69.95	69.82	67.65
Days Inventory Outstanding (DIO)	34.12	33.03	34.11	37.58	37.78	44.19	43.10	43.63	43.34	44.23
Days Payable Outstanding (DPO)	23.83	29.34	24.40	24.37	21.67	26.04	17.25	18.80	18.76	20.76
Cash Conversion Cycle (CCC)	79.37	67.74	76.01	80.83	84.08	85.89	95.77	94.78	94.40	91.12
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	5,417	5,186	5,405	5,478	5,406	5,786	5,794	5,771	5,708	5,335
Invested Capital Turnover	0.72	0.80	0.78	0.76	0.78	0.75	0.73	0.73	0.73	0.73
Increase / (Decrease) in Invested Capital	270	373	298	-15	-11	600	389	294	302	-450
Enterprise Value (EV)	12,328	13,296	12,587	12,987	12,148	14,315	16,052	12,690	12,165	11,393
Market Capitalization	9,537	11,086	10,290	10,761	10,048	12,127	13,899	10,641	10,239	9,520
Book Value per Share	$51.65	$58.50	$60.97	$63.53	$64.48	$70.12	$70.77	$72.27	$73.26	$67.69
Tangible Book Value per Share	($21.96)	($16.29)	($14.73)	($11.62)	($9.07)	($7.06)	($5.01)	($3.05)	($2.34)	($2.12)
Total Capital	5,611	5,731	5,901	5,978	5,865	6,306	6,364	6,182	6,154	5,748
Total Debt	2,939	2,708	2,744	2,678	2,514	2,647	2,660	2,409	2,327	2,240
Total Long-Term Debt	2,937	2,708	2,744	2,678	2,514	2,647	2,660	2,409	2,327	2,240
Net Debt	2,745	2,162	2,248	2,178	2,055	2,127	2,090	1,998	1,880	1,827
Capital Expenditures (CapEx)	72	89	107	67	66	78	79	39	39	76
Debt-free, Cash-free Net Working Capital (DFCFNWC)	210	114	265	297	293	277	386	373	272	214
Debt-free Net Working Capital (DFNWC)	403	347	467	497	451	554	713	552	483	409
Net Working Capital (NWC)	401	347	467	497	451	554	713	552	483	409
Net Nonoperating Expense (NNE)	22	-63	29	28	30	-69	20	25	20	96
Net Nonoperating Obligations (NNO)	2,745	2,162	2,248	2,178	2,055	2,127	2,090	1,998	1,880	1,827
Total Depreciation and Amortization (D&A)	75	78	77	78	79	81	85	86	88	102
Debt-free, Cash-free Net Working Capital to Revenue	5.54%	2.86%	6.49%	7.10%	6.96%	6.70%	9.40%	9.14%	6.71%	5.29%
Debt-free Net Working Capital to Revenue	10.66%	8.74%	11.41%	11.90%	10.69%	13.41%	17.35%	13.53%	11.88%	10.10%
Net Working Capital to Revenue	10.61%	8.74%	11.41%	11.90%	10.69%	13.41%	17.35%	13.53%	11.88%	10.10%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.90	$3.68	$2.02	$1.89	$1.70	$3.66	$1.31	$1.75	$1.34	($4.20)
Adjusted Weighted Average Basic Shares Outstanding	50.87M	50.81M	51.10M	51.22M	51.28M	51.23M	51.44M	51.55M	51.39M	51.38M
Adjusted Diluted Earnings per Share	$1.88	$3.66	$2.01	$1.89	$1.69	$3.63	$1.30	$1.74	$1.33	($4.17)
Adjusted Weighted Average Diluted Shares Outstanding	51.28M	51.30M	51.43M	51.47M	51.61M	51.45M	51.84M	51.85M	51.58M	51.63M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	50.88M	50.99M	51.18M	51.27M	51.30M	51.35M	51.51M	51.63M	51.14M	51.14M
Normalized Net Operating Profit after Tax (NOPAT)	120	126	133	127	118	120	95	119	90	-117
Normalized NOPAT Margin	12.10%	11.50%	12.94%	12.03%	11.51%	11.87%	9.37%	11.64%	8.96%	-11.71%
Pre Tax Income Margin	12.45%	22.27%	12.73%	12.14%	10.99%	20.59%	9.79%	11.66%	9.04%	-21.62%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	11.81	8.03	4.79	4.63	4.30	7.17	3.77	4.56	3.96	-6.74
NOPAT to Interest Expense	10.52	3.64	3.87	3.64	3.50	3.59	2.71	3.65	2.99	-4.16
EBIT Less CapEx to Interest Expense	5.45	5.47	1.68	2.71	2.35	4.84	1.50	3.35	2.68	-9.42
NOPAT Less CapEx to Interest Expense	4.16	1.08	0.77	1.72	1.55	1.25	0.45	2.44	1.71	-6.84
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	8.74%	7.85%	4.72%	4.93%	5.03%	5.03%	3.21%	4.14%	27.85%	471.22%

Frequently Asked Questions About Charles River Laboratories International's Financials

When does Charles River Laboratories International's financial year end?

According to the most recent income statement we have on file, Charles River Laboratories International's fiscal year ends in December. Their fiscal year 2024 ended on December 28, 2024.

How has Charles River Laboratories International's net income changed over the last 9 years?

Charles River Laboratories International's net income appears to be on an upward trend, with a most recent value of $25.29 million in 2024, falling from $151.09 million in 2015. The previous period was $480.37 million in 2023. Find out what analysts predict for Charles River Laboratories International in the coming months.

What is Charles River Laboratories International's operating income?

Charles River Laboratories International's total operating income in 2024 was $227.35 million, based on the following breakdown:

Total Gross Profit: $1.33 billion
Total Operating Expenses: $1.10 billion

How has Charles River Laboratories International revenue changed over the last 9 years?

Over the last 9 years, Charles River Laboratories International's total revenue changed from $1.36 billion in 2015 to $4.05 billion in 2024, a change of 197.1%.

How much debt does Charles River Laboratories International have?

Charles River Laboratories International's total liabilities were at $4.02 billion at the end of 2024, a 11.4% decrease from 2023, and a 208.6% increase since 2015.

How much cash does Charles River Laboratories International have?

In the past 9 years, Charles River Laboratories International's cash and equivalents has ranged from $117.63 million in 2016 to $276.77 million in 2023, and is currently $194.61 million as of their latest financial filing in 2024.

How has Charles River Laboratories International's book value per share changed over the last 9 years?

Over the last 9 years, Charles River Laboratories International's book value per share changed from 15.72 in 2015 to 67.69 in 2024, a change of 330.5%.

Related Companies

This page (NYSE:CRL) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Charles River Laboratories International (CRL) Financials

Frequently Asked Questions About Charles River Laboratories International's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Charles River Laboratories International (CRL) Financials

Annual Income Statements for Charles River Laboratories International

Quarterly Income Statements for Charles River Laboratories International

Annual Cash Flow Statements for Charles River Laboratories International

Quarterly Cash Flow Statements for Charles River Laboratories International

Annual Balance Sheets for Charles River Laboratories International

Quarterly Balance Sheets for Charles River Laboratories International

Annual Metrics and Ratios for Charles River Laboratories International

Quarterly Metrics and Ratios for Charles River Laboratories International

Frequently Asked Questions About Charles River Laboratories International's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools